The new Siemens Healthineers CMV IgG assay offers an aid in the determination of serological status and the diagnosis of CMV infection in individuals for whom a CMV IgG test was ordered, including pregnant women.
The new Atellica IM/ADVIA Centaur CMV IgG Assay can (a) produce faster results and reduce costs by reducing repeat testing with no equivocal zone; (b) achieve accuracy when determining CMV IgG patient serological status with a positive agreement of 99.6 percent and a negative agreement of 96.8 percent; and (c) reach a broader patient population at risk for CMV, with both adult and pediatric claims.
